Alnylam to Webcast Presentation at Banc Of America Securities 'New Products, New Paradigms In Health Care' Conference on July 29, 2004
CAMBRIDGE, Mass., Jul 23, 2004 /PRNewswire-FirstCall via COMTEX/ -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading therapeutic RNA interference (RNAi) company, today announced that management will be presenting a company overview at the Banc of America Securities "New Products, New Paradigms in Health Care" Conference on Thursday, July 29, 2004, at 8:45 am Eastern Time at The Southampton Inn, in Southampton, New York.
A live audio webcast of this presentation will be available on the "Investors" section of the company's website, http://www.alnylam.com. A replay of the presentation will be posted on the Alnylam website approximately three hours after the event, and will be archived for 14 days.
Alnylam is a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on RNA interference, or RNAi. Growing from its foundation as the world's first company focused on RNAi therapeutics, the company's leadership in the field of RNAi is supported by its preeminent founders and advisors and its strengths in fundamental patents, technology, and know-how that underlie the commercialization of RNAi therapeutics. Alnylam is developing a pipeline of RNAi products using Direct RNAi to treat ocular, central nervous system, and respiratory diseases and Systemic RNAi to treat a broad range of diseases, including oncology, metabolic, and autoimmune diseases. The company's global headquarters are in Cambridge, Massachusetts. For additional information, please visit http://www.alnylam.com.
SOURCE Alnylam Pharmaceuticals, Inc.
Media, Kathryn Morris of KMorrisPR, +1-845-635-9828; or
Investors, Lilian Stern of Stern Investor Relations, Inc.,
+1-212-362-1200, both for Alnylam Pharmaceuticals, Inc.